Darovasertib

Drug identity checked against registry records

Also recorded as IDE 196; IDE196; LXS196

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

TrialSponsorPhaseStatusPrimary completion
(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular MelanomaNCT05907954IDEAYA BiosciencesPhase 2Active not recruiting2027-04-30Estimated
Neoadjuvant Darovasertib in Primary Uveal MelanomaNCT07015190IDEAYA BiosciencesPhase 3Recruiting2030-10Estimated

Regulatory dates and decisions

No regulatory events match this view.This does not mean no FDA events have occurred.